Shanghai Medicilon Inc.

PDX model , full name Patient-Derived Tumor Xenograft (PDX) model, is a tumor model constructed by transplanting tumor tissue from tumor patients into immunodeficient mice and allowing the tumor tissue to grow in the mice. This model has not undergone any artificial culture, so its biological characteristics are more complete and more similar to clinical practice. It is considered to be the best tumor animal model at this moment. PDX Model Establishment Process   The establishment of PDX. a Showing the establishment process of PDX. b Showing the factors affecting the engraftment rate and the categories of PDX mice[1] The steps to build a PDX (Patient-Derived Xenograft) model usually include the following: 1. Prepare tumor tissue specimens. First, tumor tissue needs to be obtained from the patient. These tissues can be cut into 2 to 3 mm cubic fragments or made into single cell suspensions. Tumor specimens need to be washed

On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources. The "2024 Top 100 Future Healthcare" list was jointly launched by vbdata.cn, VB100, and VCBeat Research, aiming to select truly representative Chinese innovative medical practitioners who embody the future of healthcare and drive the innovative transformation process in the health and medical industry. This selection process, with a strict and fair evaluation mechanism, combines multiple stages including independent company applications, professional evaluations, cross-evaluations by supporting organizations, and final review by an expert committee. It focuses on the growth and annual performance of candidate companies across 17 secondary in

  The skin is the largest organ of the human body and the primary barrier between the body and the external environment.  Due to its direct exposure, the skin is susceptible to various influences such as the external environment, internal diseases, and genetic factors. it is susceptible to a wide range of dermatological conditions due to its direct interaction with these influences. In vitro  release testing (IVRT) and  in vitro  permeation testing (IVPT) are key pharmaceutical techniques for evaluating the pharmaceutical research of topical dermatological formulations.  These tests can help researchers understand the drug’s release and permeation characteristics on the skin, providing critical insights for the drug formulation and preparation. Are you still confused about IVRT and IVPT?  Let’s listen together to Xiaolei Yu, the project manager of the Formulation Department at Medicilon, shares the experience with us. Pharmaceutical preparation Medicilon's Preparation Department is

  On April 29th, AnDiCon Bio (AnDiCon) announced that the Phase III clinical trial of the new influenza drug Madoxanavir tablets (ADC189), which cures Type A and Type B influenza in adults and adolescents, has reached its primary endpoint, demonstrating excellent safety and efficacy." Medicilon, as a partner of AnDiCon, provided  formulation research services  for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes. This progress of Madoxanavir tablets not only validates its effectiveness and safety in treating influenza in adults and adolescents, but also indicates its enormous potential in the field of influenza treatment in children. About AnDiCon Bio The AnDiCon Bio Innovation Team, led by several academicians, focuses on the fields of respiratory anti-infection and pain.  The company has gathered a group of academic professionals and highly effici

On the journey of drug development, each collaboration is a profound test of professional competence and a severe test of professionalism.  Recently, Medicilon USA Corp. (Medicilon) is honored to have received a thank-you letter from Jingye Medicine & Chemical Co., Ltd (Jingye Medicine) and was awarded the "Best Collaboration Award". This not only recognizes the professional capabilities and service level of Medicilon, but also reflects the result of the joint efforts and tacit collaboration between the two parties. Medicilon and Jingye Medicine Work together to overcome difficulties and achieve fruitful collaboration Jingye Medicine, as a secondary safety production standardization enterprise for hazardous chemicals, continues to demonstrate outstanding professional capabilities and profound industry accumulation in the fields of pharmaceutical raw materials, pharmaceutical intermediates and CDMO project services.  In collaboration with Jingye Medicine, the Medicilon tea

  On April 30, the highly anticipated "The 4th Pharmaceutical Innovation Award" event came to a successful conclusion.  At this event gathering industry elites, Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year". Winning this honor for the third time undoubtedly represents a high recognition and affirmation of Medicilon's twenty years of empowerment in drug innovation! The "Pharmaceutical Innovation Award" is organized by the Securities Times in 2020, aiming to promote the improvement of drug innovation capabilities by selecting outstanding drug innovation projects, outstanding companies and outstanding figures in China.  The selection expert committee conducts selection based on the "Finance - Innovative Drug Index" database, drug evaluation and other related factors.

  On April 4, 2024, A Cancer Journal for Clinicians (CA), the top journal with the No. 1 impact factor, released the report "Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Rates of 36 Cancer in 185 Countries".  The report points out that there will be nearly 20 million new cancer cases worldwide in 2022, and the number of cancer deaths will be 9.7 million.  These data indicate that approximately one in five men or women will develop cancer in their lifetime, and one in 9 men and one in 12 women may die from cancer.  Predictions show that by 2050, new cancer cases worldwide may climb to 35 million, highlighting the severe challenges facing cancer treatment. April 17 is World Cancer Day and April 15-21 is National Cancer Prevention and Treatment Awareness Week.  These special days aim to draw global public attention to cancer, a serious public health issue, and to promote progress in cancer prevention and treatment.  The just-concluded 115th Annual